3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 3
1
Status
Completed
2
Not yet recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
4
OTHER
3
NETWORK
1
Study Type
Interventional
3
Observational
1
Sponsor
Cancer Type
Other hematologic neoplasm
4
Myeloid
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
17
Leukemia, Myeloid, Chronic-Phase
4
Leukemia
3
Bronchiolitis Obliterans Syndrome
3
Philadelphia Chromosome
2
Myeloproliferative Disorders
2
Recurrence
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
P1b: Advanced Solid Tumors
1
Leukemia, Myeloid
1
Hematologic Diseases
1
Blast Crisis
1
Advanced Solid Tumors
1
Interventions
Imatinib Mesylate
15
Dasatinib
14
nilotinib
8
olverembatinib
4
asciminib
4
ponatinib
3
Cyclosporine
3
bosutinib
2
Methotrexate
2
Homoharringtonine
2
Cyclophosphamide
2
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide
2
inecalcitol
1
flumatinib
1
fludarabine phosphate
1
elsulfavirine
1
Whole-Body Irradiation
1
Transplantation
1
Radiotherapy
1
Peripheral Blood Stem Cell Transplantation
1
PF-114
1
Mycophenolic Acid
1
Interferon-alpha
1
Hydroxyurea
1
Fentanyl
1
Everolimus
1
Cytarabine
1
Cord Blood Stem Cell Transplantation
1
Busulfan
1
BMS-833923
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
4 trials
Recent
Start date
Enrollment
INDUSTRY
×
Leukemia, Myeloid, Chronic-Phase
×
asciminib
×
Clear all
NCT03874858
2026-04-02
DANTE
Novartis
Phase 2
Completed
124 enrolled
NCT04666259
2025-10-16
AIM4CML
Novartis
Phase 3
Completed
56 enrolled
18 charts
NCT05384587
2025-10-14
ASC2ESCALATE
Novartis
Phase 2
Active not recruiting
34 enrolled
NCT07091019
2025-07-29
ASC4REAL-2
Novartis
Not yet recruiting
1,000 enrolled